Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out based on current evidence.
Researchers found that patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy.
Patients with pretreated microsatellite instability-high cancers treated with immune checkpoint inhibitors were found to have high activity, independent of tumor type and drug used.
This study suggested that Medicaid expansion could have survival benefits for men with non-small cell lung cancer, however the same association pattern was not observed for women.
A phase II study indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer.
A workshop group assessed the use of multidimensional data obtained from patients with cancer and the computational methods used to analyze the data.
Recommendations for patients who develop COVID-19 while receiving immunotherapy or other advanced immune-engaging therapies.
Given these findings, researchers indicated that continuous education around molecular testing in lung cancer should be intensified on both national and international levels to ensure patients receive optimal therapy.
The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.
This study found that regional- and distant-stage prostate cancer incidence continues to increase in US men aged ≥50 years.